Teva Pharmaceutical - best Pharma Stocks of 2007
Company: Teva Pharmaceutical
Starting stock price: $31.26
Ending stock price: $46.48
Percent Change: 48.69%
Details: Generic drug powerhouse Teva Pharmaceuticals had a great year in 2007. The company received FDA approval for 28 new products, including generic versions of Aricept, Requip, Actonel, Coreg, and Protonix. Teva's revenue rose 12 percent year over 2006, which was another blockbuster year for the drugmaker. And with more blockbuster drugs on their way to generics land, things can only get better for Teva.
More News:
Teva snaps up CoGenesys in $400M buyout. Report
Teva earmarks $1B for India. Report
Earnings from Schering, Sanofi, Teva. Report
Analysts get bullish on generics makers. Report
More stories about Teva Pharmaceutical
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: